Inspire Advisors LLC Buys 214 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Inspire Advisors LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 10.0% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 2,348 shares of the medical research company’s stock after purchasing an additional 214 shares during the period. Inspire Advisors LLC’s holdings in IQVIA were worth $557,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Versant Capital Management Inc grew its holdings in IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares during the period. Opal Wealth Advisors LLC purchased a new position in shares of IQVIA in the second quarter valued at about $27,000. Park Place Capital Corp purchased a new position in shares of IQVIA in the third quarter valued at about $28,000. Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA in the second quarter valued at about $29,000. Finally, Riverview Trust Co purchased a new position in shares of IQVIA in the first quarter valued at about $32,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the topic of several research analyst reports. Royal Bank of Canada initiated coverage on IQVIA in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 price objective on the stock. Evercore ISI lowered their price objective on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Robert W. Baird boosted their price objective on IQVIA from $251.00 to $256.00 and gave the company a “neutral” rating in a research report on Friday, September 20th. Redburn Atlantic began coverage on IQVIA in a research report on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective on the stock. Finally, Morgan Stanley boosted their target price on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $267.87.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the transaction, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.60% of the company’s stock.

IQVIA Trading Up 1.2 %

Shares of NYSE IQV opened at $236.61 on Friday. The business’s 50 day moving average is $239.08 and its two-hundred day moving average is $231.26. The company has a debt-to-equity ratio of 1.80, a current ratio of 0.85 and a quick ratio of 0.85. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The stock has a market capitalization of $43.13 billion, a P/E ratio of 30.73, a PEG ratio of 2.22 and a beta of 1.49.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The company had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the previous year, the firm posted $2.22 earnings per share. The firm’s revenue for the quarter was up 2.3% on a year-over-year basis. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.25 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.